| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
| 11/16/2022 | 434.38% | B. Riley Securities | $3 → $1.5 | Downgrades | Buy → Neutral |
| 05/23/2022 | 968.76% | Piper Sandler | $4 → $3 | Maintains | Overweight |
| 03/31/2022 | 1325.01% | Truist Securities | $12 → $4 | Maintains | Buy |
| 03/30/2022 | 1325.01% | Piper Sandler | $8 → $4 | Maintains | Overweight |
| 10/18/2021 | 3106.27% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 08/02/2021 | 2037.51% | JP Morgan | → $6 | Upgrades | Neutral → Overweight |
| 07/28/2021 | 4887.53% | Wells Fargo | $4 → $14 | Upgrades | Equal-Weight → Overweight |
| 03/18/2021 | 4175.03% | Truist Securities | → $12 | Initiates Coverage On | → Buy |
| 03/17/2021 | 1325.01% | Wells Fargo | $2 → $4 | Maintains | Equal-Weight |
| 02/18/2021 | 2393.77% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 02/05/2021 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 05/18/2020 | 790.63% | B. Riley Securities | $3.5 → $2.5 | Maintains | Buy |
| 05/12/2020 | 256.25% | Wells Fargo | $1.5 → $1 | Maintains | Equal-Weight |
| 03/04/2020 | 434.38% | Wells Fargo | $2.5 → $1.5 | Maintains | Equal-Weight |
| 11/18/2019 | 1146.88% | B. Riley Securities | → $3.5 | Reinstates | → Buy |
| 06/27/2019 | 968.76% | Oppenheimer | → $3 | Initiates Coverage On | → Outperform |
| 01/04/2019 | 968.76% | B. Riley Securities | → $3 | Initiates Coverage On | → Buy |
| 11/12/2018 | — | Wells Fargo | Downgrades | Outperform → Market Perform | |
| 11/12/2018 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 05/31/2018 | 1325.01% | Seaport Global | → $4 | Initiates Coverage On | → Buy |
What is the target price for Infinity Pharmaceuticals (INFI)?
The latest price target for Infinity Pharmaceuticals (NASDAQ: INFI) was reported by Piper Sandler on February 24, 2023. The analyst firm set a price target for $0.00 expecting INFI to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Infinity Pharmaceuticals (INFI)?
The latest analyst rating for Infinity Pharmaceuticals (NASDAQ: INFI) was provided by Piper Sandler, and Infinity Pharmaceuticals downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Infinity Pharmaceuticals (INFI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Infinity Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Infinity Pharmaceuticals was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
Is the Analyst Rating Infinity Pharmaceuticals (INFI) correct?
While ratings are subjective and will change, the latest Infinity Pharmaceuticals (INFI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Infinity Pharmaceuticals (INFI) is trading at is $0.28, which is out of the analyst's predicted range.
